Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: Rapidly improving stroke symptoms

Stroke

Volumn 44, Issue 9, 2013, Pages 2500-2505

  Levine, Steven R ^a   Khatri, Pooja ^b   Broderick, Joseph P ^b   Grotta, James C ^c   Kasner, Scott E ^d   Kim, Doojin ^e   Meyer, Brett C ^f   Panagos, Peter ^g   Romano, Jose ^h   Scott, Phillip ⁱ  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cerebral infarction; Clinical trials; Patient selection; Thrombolysis; TIA; Tissue type plasminogen activator

Indexed keywords

ALTEPLASE; GLUCOSE;

ARTERY PUNCTURE; BOLUS INJECTION; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONSENSUS; DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG INFUSION; DRUG PACKAGING; E-MAIL; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; GLUCOSE BLOOD LEVEL; HUMAN; INTERVIEW; MAJOR SURGERY; MEANINGFUL USE CRITERIA; MEDICAL HISTORY; NEUROLOGICAL COMPLICATION; PHYSICIAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; TRANSIENT ISCHEMIC ATTACK; URINARY TRACT HEMORRHAGE;

CEREBRAL INFARCTION; CLINICAL TRIALS; PATIENT SELECTION; THROMBOLYSIS; TIA; TISSUE-TYPE PLASMINOGEN ACTIVATOR;

ADVISORY COMMITTEES; CLINICAL TRIALS AS TOPIC; CONSENSUS; FIBRINOLYTIC AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INJECTIONS, INTRAVENOUS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 84884467113     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.000878     Document Type: Review

References (29)

1. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
2. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23:641-645.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med. 1995;333:1581-1587.
4. Genentech, Inc. Activase for Acute Ischemic Stroke, 2012. http://www.activase.com/iscstroke/index.jsp. Accessed September 6, 2012.
5. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissuetype plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke. 2011;42:1952-1955.
6. Smith EE, Fonarow GC, Reeves MJ, Cox M, Olson DM, Hernandez AF, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke. 2011;42:3110-3115.
7. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
8. Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005;36:2497-2499.
9. Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med. 2006;31(6 suppl 2):S210-S216.
10. Balucani C, Levine SR. Mild stroke and rapidly improving symptoms: it's not always a happy ending. Stroke. 2011;42:3005-3007.
11. Nedeltchev K, Schwegler B, Haefeli T, Brekenfeld C, Gralla J, Fischer U, et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke. 2007;38:2531-2535.
12. Engelter ST, Gostynski M, Papa S, Ajdacic-Gross V, Lyrer PA. Barriers to stroke thrombolysis in a geographically defined population. Cerebrovasc Dis. 2007;23:211-215.
13. George MG, Tong X, McGruder H, Yoon P, Rosamond W, Winquist A, et al; Centers for Disease Control and Prevention (CDC). Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007. MMWR Surveill Summ. 2009;58:1-23.
14. Jacobs DG, Sarafin JL, Huynh T, Miles WS, Sing RF, Thomason MH. Audience response system technology improves accuracy and reliability of trauma outcome judgments. J Trauma. 2006;61:135-41; discussion 141.
15. Uhari M, Renko M, Soini H. Experiences of using an interactive audience response system in lectures. BMC Med Educ. 2003;3:12.
16. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947.
17. Alexandrov AV, Felberg RA, Demchuk AM, Christou I, Burgin WS, Malkoff M, et al. Deterioration following spontaneous improvement: sonographic findings in patients with acutely resolving symptoms of cerebral ischemia. Stroke. 2000;31:915-919.
18. Rajajee V, Kidwell C, Starkman S, Ovbiagele B, Alger JR, Villablanca P, et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology. 2006;67:980-984.
19. Coutts SB, O'Reilly C, Hill MD, Steffenhagen N, Poppe AY, Boyko MJ, et al; Calgary CTA Study Group. Computed tomography and computed tomography angiography findings predict functional impairment in patients with minor stroke and transient ischaemic attack. Int J Stroke. 2009;4:448-453.
20. Grotta JC, Welch KM, Fagan SC, Lu M, Frankel MR, Brott T, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke. 2001;32:661-668.
21. Levine SR, Khatri P, Khoury J, Saver JL, Broderick JP. Rapidly improving stroke symptoms: a controversial exclusion criteria for tPA. Stroke. 2011;42:e86.
22. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al; American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276-2293.
23. Pedrono E, Durukan A, Strbian D, Marinkovic I, Shekhar S, Pitkonen M, et al. An optimized mouse model for transient ischemic attack. J Neuropathol Exp Neurol. 2010;69:188-195.
24. Levy DE. How transient are transient ischemic attacks? Neurology. 1988;38:674-677.
25. Leira EC, Pary JK, Davis PH, Grimsman KJ, Adams HP Jr. Slow progressive acceptance of intravenous thrombolysis for patients with stroke by rural primary care physicians. Arch Neurol. 2007;64:518-521.
26. Khatri P, Kleindorfer DO, Yeatts SD, Saver JL, Levine SR, Lyden PD, et al. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke. 2010;41:2581-2586.
27. Martin-Schild S, Albright KC, Tanksley J, Pandav V, Jones EB, Grotta JC, et al. Zero on the NIHSS does not equal the absence of stroke. Ann Emerg Med. 2011;57:42-45.
28. Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A, et al VISTA Collaborators. Thrombolysis in stroke despite contraindications or warnings? Stroke. 2013;44:727-733.
29. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368: 914-923.